BACKGROUND:Finasteride, a type II-selective 5alpha-reductase inhibitor, as a causative agent of decreasing dihydroxy testosterone (DHT) level, is effective in the treatment of male androgenic alopecia. AIM: We compared the local and oral finasteride in the treatment of androgenic alopecia. METHOD: This is a double blind, randomized clinical trial study of 45 male patients, who were referred with alopecia to the private clinics and departments in Boo-Ali Sina Hospital, in Sari. Patients with male androgenic alopecia were selected according to the history and physical examinations. The patients were randomly divided into two: topical finasteride (A) and oral finasteride (B) groups. Topical finasteride group (A) received a topical gel of 1% finasteride and placebo tablets, while the oral finasteride group (B) received finasteride tablets (1 mg) and gel base (without drug) as placebo for 6 months. The patients were followed by clinical observation and recording of side effects prior to the treatment and at the end of first week, and then by a monthly follow-up. The size of bald area, total hair count, and terminal hair were studied. Data were analyzed by descriptive and Chi-square statistical test. RESULTS: The mean duration of hair loss was 18.8+/-23.10 months. Each month the terminal hair, size of bald area and hair count between the two groups were compared. There were no significant differences between the two groups as a viewpoint of hair thickness, hair counts and the size of bald area. Serial measurements indicated a significant increase in hair counts and terminal hair counts between the two groups. CONCLUSIONS: The results of this study showed that the therapeutic effects of both finasteride gel and finasteride tablet were relatively similar to each other.
RCT Entities:
BACKGROUND:Finasteride, a type II-selective 5alpha-reductase inhibitor, as a causative agent of decreasing dihydroxy testosterone (DHT) level, is effective in the treatment of male androgenic alopecia. AIM: We compared the local and oral finasteride in the treatment of androgenic alopecia. METHOD: This is a double blind, randomized clinical trial study of 45 male patients, who were referred with alopecia to the private clinics and departments in Boo-Ali Sina Hospital, in Sari. Patients with male androgenic alopecia were selected according to the history and physical examinations. The patients were randomly divided into two: topical finasteride (A) and oral finasteride (B) groups. Topical finasteride group (A) received a topical gel of 1% finasteride and placebo tablets, while the oral finasteride group (B) received finasteride tablets (1 mg) and gel base (without drug) as placebo for 6 months. The patients were followed by clinical observation and recording of side effects prior to the treatment and at the end of first week, and then by a monthly follow-up. The size of bald area, total hair count, and terminal hair were studied. Data were analyzed by descriptive and Chi-square statistical test. RESULTS: The mean duration of hair loss was 18.8+/-23.10 months. Each month the terminal hair, size of bald area and hair count between the two groups were compared. There were no significant differences between the two groups as a viewpoint of hair thickness, hair counts and the size of bald area. Serial measurements indicated a significant increase in hair counts and terminal hair counts between the two groups. CONCLUSIONS: The results of this study showed that the therapeutic effects of both finasteride gel and finasteride tablet were relatively similar to each other.
Authors: Francesca Lolli; Francesco Pallotti; Alfredo Rossi; Maria C Fortuna; Gemma Caro; Andrea Lenzi; Andrea Sansone; Francesco Lombardo Journal: Endocrine Date: 2017-03-28 Impact factor: 3.633